Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Zoetis Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.4 (market cap $41.13B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: iShares 7-10 Year Treasury Bond ETF is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Zoetis Inc for 70 Days on average.
| IEF | ZTS | |
|---|---|---|
Market Cap | $41.13B | $30.20B |
Volume | 10,340,382 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $147.53 |
52-Week Low | $88.92 | $69.09 |
Typical Hold Time | 108 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.45, up 0.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 52.94, while ADX indicates strong bearish momentum. Recent dividend payments of $0.31-$0.33 provide income support amid challenging bond market conditions. Key support sits at $89 with resistance at $90, creating a tight trading range.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current levels may offer entry points for income-focused investors, persistent inflation and Fed policy uncertainty pose significant risks. The bearish technical setup suggests continued pressure unless macroeconomic conditions improve.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
